Neuroendocrine carcinoma of prostate

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-1) 1 substance
Phase II: 1 Phase I (Other): 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • Fundación Oncosur Academic
    PEMBROLIZUMAB
    2022-501139-17-01 1 country 2023 n=42
    Ended

Phase I (Other)

1 trial
  • Amgen Inc. Commercial
    IMP not specified
    2024-513316-10-00 3 countries 2021 n=11
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 1 Phase I (Other) 0
Fundación Oncosur Academic 1 Phase II 0
New trials by year
2021
1
2023
1
← All indication landscapes